Login
Companies $AGEN
$6.35 +$0.06 (0.95%) After hours
AGENUS INC logo

AGENUS INC

agenusbio.com

What Do They Do?

Develops antibody-based immunotherapies for cancer and infectious disease for patients, alongside vaccine adjuvants for vaccine developers.

Who Are Their Customers?

Patients receive BOT+BAL through authorized access programs at hospitals and through physicians; pharmaceutical companies work with Agenus through collaboration and licensing agreements for antibody programs.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 73% from one customer

Do Revenues Turn Into Profits?

Yes. It kept less than a cent of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$77.2M.

Operating income, FY2025
−18% of revenue
▲ +83% (Loss) vs FY2024 (−$120.5M, −116%)
Net income, FY2025
0% of revenue
▲ Turned profitable vs FY2024 (−$227.2M, −220%)
Free cash flow, FY2025
−68% of revenue
▲ +51% (Loss) vs FY2024 (−$158.9M, −154%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +4%
vs $30.2M in Q3 FY2025
Net income
▼ −96%
vs $63.9M in Q3 FY2025
Non-cash royalty revenue share of revenue vs 96.4% in Q3 FY2025

A narrower development focus The older report described a broad pipeline of antibodies, cell therapies and vaccine adjuvants, supported by in-house manufacturing. The latest report prioritizes BOT/BAL and says some other preclinical and clinical work is paused while Agenus evaluates partners.

Manufacturing moved toward collaborations The older report highlighted in-house cGMP manufacturing; the latest says Agenus sold its Emeryville and Berkeley biologics facilities to Zydus and will maintain manufacturing flexibility through collaborations.

Revenue over time
Pre-Commercial Product Revenue Clinical product revenue Other services Non-cash royalties Recognition of deferred research and development revenue Recognition of Deferred Grant Revenue License fees and milestones Research and development services Royalty sales milestone
$500M$250M$0

Who Do They Compete With?

Competes with Bristol Myers Squibb, Merck &, Regeneron Pharmaceuticals, Roche / Genentech, AstraZeneca, Merck KGaA, GSK, Coherus BioSciences, Incyte, BeiGene, Checkpoint Therapeutics, Akeso Biopharma, CStone Pharmaceuticals, Harbour BioMed, Innovent Biologics, AbbVie, Amgen, Novartis, Pfizer, and Sanofi

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support